There were no clear benefits of using faster insulin aspart in closed-loop insulin therapy and the closed-loop algorithm was better adjusted to the use of standard insulin aspart.
A glycated hemoglobin (HbA1c) target value of <6.5 percent does not offer additional protection against organ complications for patients with type 1 diabetes compared with a target of 6.5 to 6.9 percent.
Hepatic-directed vesicle insulin, a novel liver-targeted rapid-acting insulin formulation for type 1 diabetes, is noninferior to insulin lispro for improvement of HbA1c and is associated with a lower hypoglycemia risk in some patients.
ADO09, a coformulation of amylin analog pramlintide and A21G human insulin, is superior to insulin lispro for reducing postprandial blood glucose in patients with type 1 diabetes.
Researchers found approximately one-third of patients with type 1 diabetes and celiac disease were able to achieve sustained celiac-specific antibody negativity after celiac disease diagnosis.
Type 1 diabetes diagnosis is missed less frequently when patients present during childhood or adolescence, but unlike in adults, misdiagnosis in childhood is associated with an increased likelihood of diabetic ketoacidosis.
The FDA has granted Breakthrough Therapy designation to teplizumab (PRV-031; Provention Bio), for the prevention or delay of clinical T1D in those at risk of developing the disease.
In young patients with type 1 diabetes, phenotypes of body mass index and glycemic control are associated with patterns of early diabetes complications.
Researchers aimed to determine the optimal BP threshold to minimize the risk for coronary artery disease events in young patients with childhood-onset T1D.
Measurement of serum apolipoprotein levels in apolipoprotein-defined lipoprotein subclasses may have an important role in predicting vascular complications in T1D.
There is a correlation between a high level of amyloid-producing Escherichia coli in the intestines and the initiation of autoimmunity and type 1 diabetes progression.
